<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-125649" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gallium Scan</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dittrich</surname>
            <given-names>Richard P.</given-names>
          </name>
          <aff>Southend University Hospital NHS Foundation Trust</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Jesus</surname>
            <given-names>Orlando</given-names>
          </name>
          <aff>University of Puerto Rico, Medical Sciences Campus, Neurosurgery Section</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Dittrich declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Orlando De Jesus declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-125649.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A gallium scan is a study that uses intravenously injectable isotopes of gallium to produce nuclear medicine images. Gallium was&#x000a0;1 of the first radioisotopes used for diagnostic nuclear medicine. Gallium, discovered in 1875 by Paul-&#x000c9;mile Lecoq de Boisbaudran, was first considered for diagnostic and therapeutic&#x000a0;medical use in the 1940s by the research of H. C. Dudley and his co-workers. Gallium scans were initially used for localizing tumors and abscesses. Commercially available radiopharmaceuticals gallium-67 (67Ga) and gallium-68 (68Ga) are widely used. Although gallium-72 proved less useful for medical use, gallium-67, produced by proton-bombarded zinc, and particularly gallium-68, produced by generator accelerating of germanium-68 (68Ge), emerged as solid contenders after measurement instrumentation became more advanced. Initially, gallium-67 was unexpectedly found to highlight Hodgkin&#x02019;s lymphoma, although it was intended for osseous cancer. It was later realized that the isotope could be used for a broader range of malignancies and inflammatory processes.<xref ref-type="bibr" rid="article-125649.r1">[1]</xref>&#x000a0;Historically, gallium-67 scans were used to diagnose many diseases, including bone infections, cancers (especially lymphomas), fevers of unknown origin, non-specific inflammation, and intra-abdominal abscesses. It was also used to evaluate inflammatory diseases of the lungs, like sarcoidosis, interstitial pneumonitis, pulmonary tuberculosis, and pulmonary fibrosis.<xref ref-type="bibr" rid="article-125649.r2">[2]</xref>&#x000a0;Gallium-67 is used with single-photon emission computed tomography (SPECT), while gallium-68 is used with positron emission tomography (PET).</p>
        <p>Gallium is a trivalent metal treated similarly to the body's ferric iron. Gallium-67 is relatively insoluble at normal pH and requires substances like citrate ions to form a complex to dissolve once in the body. Roughly 75% of the administered dose remains in the body after 48-72 hours and distributes evenly in soft tissues, liver, and bone. Around 90% of 67Ga is bound to transferrin in the blood plasma. Subsequently, it dissociates at low pH (exudate or tumor site) and binds to lactoferrin due to increased vascular flow in the area. White blood cells may bind and transport 67Ga as well. Siderophores produced by bacteria have a good affinity for 67Ga and can form a complex to be taken up by the bacteria. It is also thought that bacteria directly uptake 67Ga via facilitated diffusion and nonspecific binding sites.<xref ref-type="bibr" rid="article-125649.r3">[3]</xref>&#x000a0;</p>
        <p>Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes. It can be generated from germanium-68 or zinc-68. It can be used for the inherent properties in the radiometal itself or the chelated agent's chemical properties (most commonly a somatostatin analog). It is often attached to a specific chelating agent to be used as a tracer (eg, DOTA-octreotate, also known as DOTATATE). The agent keeps gallium stably bound and free to distribute while binding to a specific receptor molecule. DOTATATE, DOTATOC, and DOTANOC are also referred to as GaTate, GaToc, and GaNoc, respectively. Bifunctional chelating binds the metal (68Ga3+ ion) to a complex. The complex should have a high affinity with gallium for in vivo&#x000a0;stability. In contrast, the targeting biomolecule (ex., drug, peptide, or antibody) in the complex can bind to a specific site and concentrate there. Essentially, gallium is paired with a compound that binds to a target tissue site. The complex is injected intravenously and is imaged with a PET detector at specific times depending on the desired target site uptake, but usually after&#x000a0;1 hour.&#x000a0;In the case of GaTate, affinity is highest to the somatostatin receptor (SSTR) subtype 2. This leads to intense uptake in the spleen, adrenal glands, kidneys (not due to SSTR), and pituitary, with moderate intensity in the liver (not due to SSTR), thyroid, and saliva glands. There is also uptake in other areas, such as the pancreas, bone, brain, and lymph nodes.<xref ref-type="bibr" rid="article-125649.r4">[4]</xref>&#x000a0;GaToc has a high affinity to SSTR subtype 5, and GaNoc has a high affinity to SSTR subtypes 3 and 5. A homogenous uptake is physiologic, while intense heterogeneous, irregular focal uptake is worrying. The PET scan is usually done with a whole-body computed tomography (CT) scan for detailed anatomical mapping, referred to as a PET/CT scan.</p>
        <p>The renewed interest in gallium is due to its widespread availability as it is generator-produced and has a short half-life. Using gallium, on-site labeling, and radiopharmaceutical use can be done without a cyclotron nearby or delivering the product. The radiolabel pair has varying sensitivity and specificity inherent to the tissue or receptor properties.<xref ref-type="bibr" rid="article-125649.r5">[5]</xref>&#x000a0;DOTATATE has recently been given orphan drug status, which has also renewed some interest in gallium-68.</p>
        <p>Gallium-67 is a gamma-emitting isotope with a half-life of 3.26 days that was used for imaging many pathologies, although now, fluorine-18 (18F) fluoro-deoxyglucose (FDG) (18F-FDG) has mostly replaced it. Both isotopes require a high-energy cyclotron for production and for doses to be individually purchased; therefore, they are not always available.&#x000a0;18F-FDG, a nonspecific metabolic indicator using glucose metabolism, has mostly replaced gallium-67, but recently, there have been new developments in gallium&#x02019;s utility, now as a gallium-68 labeled radiotracer. This evolution includes a shorter half-life, on-site generation, somatostatin receptor, prostate (68Ga-PSMA-11 PET/MR) tracers, and other cancer diagnoses, including bony and soft tissue metastasis.<xref ref-type="bibr" rid="article-125649.r6">[6]</xref><xref ref-type="bibr" rid="article-125649.r7">[7]</xref>&#x000a0;Gallium-67 (67Ga) is still used for imaging inflammation and granulomatous reactions. It produces low resolution and image quality and has a high radiation burden to patients due to its longer half-life. Imaging takes place at least&#x000a0;2 days after injection due to this long half-life. Gallium-67 is commonly bonded with citrate or nitrate (both dissociate in the blood when injected, leaving the gallium ion, 67Ga3+).&#x000a0;Although WBC SPECT imaging has mostly replaced gallium-67 for infection imaging, there are still specific circumstances for it to be used. Examples include ruling out false negatives in spinal infections, immunocompromised patients, and chronic infections.<xref ref-type="bibr" rid="article-125649.r8">[8]</xref></p>
        <p>Gallium-68 is typically created by a 68Ge/68Ga generator. This process has an advantage over 18F-FDG, as 68Ga does not require a nearby cyclotron, and the parent isotope 68Ge has a half-life of 271 days. 68Ge is usually made from proton bombardment of 69Ga.<xref ref-type="bibr" rid="article-125649.r9">[9]</xref> 68Ge decays through electron capture. 68Ga mostly decays through positron emission (yields 89%)&#x000a0;with a mean MeV of 0.89 and maximum energy of 1.9MeV.<xref ref-type="bibr" rid="article-125649.r10">[10]</xref> That is higher energy than 18F (with positron yield 96.7%), 0.25 MeV and max 0.63MeV. Since lower positron emission yields and higher endpoint energy emission lead to lower resolution in PET scans, Gallium has a theoretically lower resolution in imaging. Gallium has lower sensitivity and inferior spatial resolution than 18F, but gallium has a high clinical image contrast when labeled, making lesion detection easier.<xref ref-type="bibr" rid="article-125649.r10">[10]</xref>&#x000a0;Moreover, both radionuclides produce high-quality imaging as long as a 3mm detection scanner is used.<xref ref-type="bibr" rid="article-125649.r11">[11]</xref>&#x000a0;Imaging can occur in approximately&#x000a0;1 hour due to the short half-life. The 68Ga3+ cation allows it to join various molecules using oxygen, nitrogen, and sulfur as atom donors. Due to increased gallium-68 demands, it can also be created by a medical cyclotron.<xref ref-type="bibr" rid="article-125649.r12">[12]</xref>&#x000a0;Originally, 68Ga was paired with ligands such as EDTA (ethylenediaminetetraacetic acid) derivatives, and years later, developed pairing with DTPA (diethylenetriaminepentaacetic acid) or DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)-based derivatives. This allowed 68Ga-DOTA-octreotate to become an alternative to Indium-111-DTPA-octreoscan.<xref ref-type="bibr" rid="article-125649.r13">[13]</xref>&#x000a0;68Ga can be paired with many molecules, including citrate, which gives it the same site affinities as 67Ga but a lower half-life. There are currently trials pairing 68Ga with antimicrobials such as ciprofloxacin and DOTA-depsidomycin.<xref ref-type="bibr" rid="article-125649.r8">[8]</xref></p>
      </sec>
      <sec id="article-125649.s2" sec-type="Procedures">
        <title>Procedures</title>
        <p>Before the procedure begins, the medical team reviews the patient's critical medical information. The patient is informed in detail of the procedure, and with the agreement, the study begins. Food and liquid restrictions are not required, but the patient should be well-hydrated and have regular bowel movements. The kidneys eliminate the 68Ga-DOTA-conjugates, while the kidneys and bowel eliminate the 67Ga-citrate.</p>
        <p>The radiopharmaceutical agent is delivered intravenously to the patient with no interacting substances. The activity administered should be above 100MBq, but it can range from 100-200MBq. For example, 67Ga should be 185MBq, 5mCi in adults, and 3.7-7.4MBq/kg, 0.1&#x000a0;to 0.2mCi/kg in children.<xref ref-type="bibr" rid="article-125649.r14">[14]</xref>&#x000a0;The time before scanning depends on the compound used. Usually, between 45 minutes to 90 minutes for 68Ga bound compounds varies depending on the desired target organ uptake and the compound used. Images for 67Ga are taken 48 hours after administration, then 72 hours for delayed images, and even up to 5 days after to help differentiate lesions.</p>
        <p>The patient should void their bladder before scanning to remove unbound radioactive compounds and reduce image noise, allowing better imaging of the area and decreasing radiation exposure to the urinary tract. Metals on the body are also removed during the procedure due to their potential for imaging interference. The patient's whole body is imaged with typical imaging times of approximately 30 to 60 minutes per view, but it depends on the size. The patient should remain still and quiet during imaging to reduce motion artifacts. The patient is discharged after the scan is completed&#x000a0;when the radiation emission levels are safe and reviewed by the physician.</p>
        <p>The patient should avoid contact with pregnant women and infants for as long as the physician advises. A waiting period of 7 half-lives allows less than 1% of original radiation to persist. This guide can also be used as a general safety rule during breastfeeding. The nuclear radiologist uses the patient's acquired relevant history to report the image in detail.</p>
      </sec>
      <sec id="article-125649.s3" sec-type="Indications">
        <title>Indications</title>
        <p>Neuroendocrine tumors (68Ga-DOTA-TATE, DOTA-NOC, DOTA-TOC): 68Ga conjugates should be used as the preferred functional imaging modality for the evaluation of neuroendocrine tumors (NETs) for all histological grades.<xref ref-type="bibr" rid="article-125649.r15">[15]</xref><xref ref-type="bibr" rid="article-125649.r16">[16]</xref>&#x000a0;Ideally, it is used alone for histological well-differentiated/low-grade tumors; however, if the tumor is not well-differentiated, it should be used with the 18F-FDG PET/CT scan.<xref ref-type="bibr" rid="article-125649.r16">[16]</xref><xref ref-type="bibr" rid="article-125649.r17">[17]</xref><xref ref-type="bibr" rid="article-125649.r18">[18]</xref><xref ref-type="bibr" rid="article-125649.r19">[19]</xref><xref ref-type="bibr" rid="article-125649.r20">[20]</xref>&#x000a0;NETs include pituitary adenoma, pancreatic islet cell tumors, carcinoid, pheochromocytoma, paraganglioma, medullary thyroid cancer, and small cell lung carcinoma.<xref ref-type="bibr" rid="article-125649.r5">[5]</xref></p>
        <p>Prostate cancer: (68Ga-labeled inhibitors of prostate-specific membrane antigen (68Ga-PSMA), 68Ga-bombesin/68Ga-RM2, 68Ga-DOTATOC)&#x000a0;<xref ref-type="bibr" rid="article-125649.r17">[17]</xref><xref ref-type="bibr" rid="article-125649.r20">[20]</xref><xref ref-type="bibr" rid="article-125649.r21">[21]</xref></p>
        <p>67Ga-citrate is mainly used for lymphomas (Hodgkin&#x02019;s and non-Hodgkin&#x02019;s) and fever of unknown origin. Although more effective agents exist, they can still be used for lung cancer, lung inflammatory diseases, bone infections, melanoma, germ cell tumors, hepatocellular carcinoma, neuroblastoma, multiple myeloma, sarcoma, and head and neck tumors. 67Ga is only used for spinal infections when FDG cannot be performed.<xref ref-type="bibr" rid="article-125649.r22">[22]</xref></p>
        <p>Emerging indications for 68Ga:</p>
        <list list-type="bullet">
          <list-item>
            <p>68Ga-DOTATATE may play a role in other somatostatin receptor tumors such as renal cell cancer, breast cancer, prostate cancer, malignant lymphoma, hepatocellular cancer, medulloblastoma, neuroblastoma, sarcoma, and gastric cancer.<xref ref-type="bibr" rid="article-125649.r23">[23]</xref><xref ref-type="bibr" rid="article-125649.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Meningioma (68-DOTATATE)&#x000a0;<xref ref-type="bibr" rid="article-125649.r17">[17]</xref><xref ref-type="bibr" rid="article-125649.r24">[24]</xref><xref ref-type="bibr" rid="article-125649.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Osteomyelitis and discitis (68Ga-citrate)&#x000a0;<xref ref-type="bibr" rid="article-125649.r26">[26]</xref><xref ref-type="bibr" rid="article-125649.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p>Breast cancer (68Ga-bombesin, 68Ga-ABY-002)&#x000a0;<xref ref-type="bibr" rid="article-125649.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p>Melanoma (68Ga-melanocortin)&#x000a0;<xref ref-type="bibr" rid="article-125649.r29">[29]</xref><xref ref-type="bibr" rid="article-125649.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Tumor therapy response (68Ga binding to DOTA-related analogs such as P-glycoprotein, cholecystokinin, neurotensin, and substance P)&#x000a0;<xref ref-type="bibr" rid="article-125649.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Pathologic angiogenic processes (68Ga-RGB, arginine, glycine, aspartic acid peptides)&#x000a0;<xref ref-type="bibr" rid="article-125649.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Alzheimer&#x02019;s disease (68Ga-DOTA-C3-BF)&#x000a0;<xref ref-type="bibr" rid="article-125649.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Cerebral amyloid angiopathy&#x000a0;<xref ref-type="bibr" rid="article-125649.r32">[32]</xref></p>
          </list-item>
          <list-item>
            <p>Pathology with activated macrophages (68Ga-deferoxamine-folate). Crohn&#x02019;s disease, rheumatoid arthritis, systemic lupus erythematosus, diabetes, vasculitis, sarcoidosis, and atherosclerosis.<xref ref-type="bibr" rid="article-125649.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Cardiac imaging (68Ga-NOTA/DOTA-RGD, 68Ga-DOTAVAP-PEG-P). Myocarditis, atherosclerotic plaques, and post-myocardial infarction inflammation&#x000a0;<xref ref-type="bibr" rid="article-125649.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Respiratory imaging (68Ga-DOTA-NOC) in&#x000a0;pulmonary fibrosis and (68Ga-DOTATATE) in&#x000a0;sarcoidosis&#x000a0;<xref ref-type="bibr" rid="article-125649.r8">[8]</xref><xref ref-type="bibr" rid="article-125649.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease (68Ga-Citrate)&#x000a0;<xref ref-type="bibr" rid="article-125649.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Colorectal, esophagus, breast, lung, pancreatic, head, and neck cancers (68Ga-fibroblast-activation-protein inhibitors) (68Ga-FAPI)&#x000a0;<xref ref-type="bibr" rid="article-125649.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Pulmonary embolism (68Ga-carbon nanoparticles and 68Ga-macro-aggregated albumin)&#x000a0;<xref ref-type="bibr" rid="article-125649.r35">[35]</xref><xref ref-type="bibr" rid="article-125649.r36">[36]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-125649.s4" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>Blood transfusions and hemolysis can interfere with the body's iron distribution; thus, it is not recommended to have a gallium-citrate scan after a recent transfusion due to uptake anomalies. Depending on the conjugated molecule for 68Ga scans, metabolic interference from various substances could occur. For example, therapeutic somatostatin analogs may interfere with 68Ga-DOTATATE scans, so if possible, short-acting somatostatin analogs should be stopped 24 hours before the scan.</p>
        <p>Motion artifacts may be a source of error. Other sources of error include but are not limited to misinterpreting physiological uptake areas, anatomical uptake variation, clothing and skin contamination with urine, recent procedures or trauma, recent or current chemotherapy, medication-related uptake changes (ex. somatostatin analogs decreasing uptake of 68Ga-DOTATATE, or granulocyte-colony stimulating factor increasing bone uptake of gallium), and rarely instrumentation calibration error (eg, PET/CT superimposition error).<xref ref-type="bibr" rid="article-125649.r25">[25]</xref></p>
      </sec>
      <sec id="article-125649.s5" sec-type="Complications">
        <title>Complications</title>
        <p>Some rare allergic reactions can occur and include but are not limited to erythema, rash, pruritis, nausea, vomiting, tachycardia, dizziness, and syncope.<xref ref-type="bibr" rid="article-125649.r37">[37]</xref><xref ref-type="bibr" rid="article-125649.r38">[38]</xref></p>
        <p>There are no contraindications to the gallium scan, but precautions should be taken to avoid complications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Whether suspected or confirmed, a clinical decision of risks versus benefits must be made during pregnancy.</p>
          </list-item>
          <list-item>
            <p>Breastfeeding should be discontinued, with milk extraction post-procedure, and resumed when the radiation dose to the child is less than 1mSv. It is recommended to wait 8 hours after the 68Ga scan before milk extraction, and breastfeeding should resume.</p>
          </list-item>
          <list-item>
            <p>Pediatric cases should be carefully evaluated to avoid radiation exposure unless there is a clear suspicion of malignancy.</p>
          </list-item>
          <list-item>
            <p>It may be beneficial to cease somatostatin analog therapy before a DOTA scan.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-125649.s6" sec-type="Patient Safety and Education">
        <title>Patient Safety and Education</title>
        <p>Radioactive gallium isotopes are inherently hazardous to one's health. Both healthcare staff and patients must be aware of the dangers and take reasonable precautions. The patient should be informed that the risk of radiation exposure is less than the scan's benefits and should understand why the scan is indicated. They should also understand others' risks when they emit radiation, especially to children, during lactation and pregnancy. The patient should be encouraged to ask questions about safety concerns.</p>
        <p>Organs have different uptake of the isotope, and there are individual variations as well. For example, a patient post-splenectomy would have higher uptake in other organs. The average effective whole-body dose of 67Ga is 18.5mSv, while 68Ga-DOTATATE is 3.0mSv.<xref ref-type="bibr" rid="article-125649.r39">[39]</xref><xref ref-type="bibr" rid="article-125649.r40">[40]</xref>&#x000a0;With a comparatively significant reduction in effective dose, 68Ga is starting to have lower exposure to adverse outcomes.<xref ref-type="bibr" rid="article-125649.r41">[41]</xref></p>
      </sec>
      <sec id="article-125649.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Until recently, gallium scans could detect many pathologies, but they have been phased out due to newer developments (eg, 18F-FDG). Gallium was limited to detecting cancer and inflammatory processes only, but now the gallium redux is expanding to detect all kinds of pathology with gallium-68 as a radiotracer. Gallium scans are adjuncts for diagnosis, although some conjugates have specific receptors. Gallium is distributed in the body according to the conjugate used. If citrate is used, gallium's natural properties allow the body to metabolize it like ferric iron.</p>
        <p>If gallium is chelated with other molecules (eg, DOTATATE), it distributes in the body according to the receptor's affinity for that molecule. An abnormal accumulation of gallium implies a localization of underlying pathology, either tumor or inflammation with citrate as a conjugate or specific pathologies (eg, NETs), depending on the conjugate molecule.</p>
        <p>68Ga can be conjugated with various molecules to help diagnose multiple pathologies. It is primarily used for cancer detection (NETs and prostate cancer). It can detect stage, post-treatment response, and cancer surveillance. It can be used&#x000a0;alone but is usually complementary to other imaging methods (ex. 18F-FDG PET, CT, MRI, etc.) for more detailed anatomy and specificity. Further developments and research may allow gallium-68 scans to adequately diagnose pulmonary embolisms, cardiac pathologies, respiratory pathologies, Alzheimer's disease, bone infections, and other cancers.</p>
        <p>67Ga-citrate is primarily used to help diagnose lymphomas (Hodgkin's and non-Hodgkin's, especially for restaging) and fevers of unknown origin. It may also be used in certain cancers (eg, bronchogenic carcinoma), although 18F-FDG has superseded it.</p>
      </sec>
      <sec id="article-125649.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=125649&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=125649">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/125649/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=125649">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-125649.s9">
        <title>References</title>
        <ref id="article-125649.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayes</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>The medical use of gallium radionuclides: a brief history with some comments.</article-title>
            <source>Semin Nucl Med</source>
            <year>1978</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-91</page-range>
            <pub-id pub-id-type="pmid">362533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forgacs</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The gallium scan and inflammatory lesions.</article-title>
            <source>Arch Intern Med</source>
            <year>1982</year>
            <month>Feb</month>
            <volume>142</volume>
            <issue>2</issue>
            <fpage>231</fpage>
            <pub-id pub-id-type="pmid">7059247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldsmith</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Vallabhajosula</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications.</article-title>
            <source>Semin Nucl Med</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-10</page-range>
            <pub-id pub-id-type="pmid">19038596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuyumcu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000d6;zkan</surname>
                <given-names>ZG</given-names>
              </name>
              <name>
                <surname>Sanli</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mudun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Adalet</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation.</article-title>
            <source>Ann Nucl Med</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>538</fpage>
            <page-range>538-45</page-range>
            <pub-id pub-id-type="pmid">23543506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banerjee</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pomper</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Clinical applications of Gallium-68.</article-title>
            <source>Appl Radiat Isot</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>76</volume>
            <fpage>2</fpage>
            <page-range>2-13</page-range>
            <pub-id pub-id-type="pmid">23522791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Zacharias</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Kunder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hatami</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Giesel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ghanouni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Loening</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sonn</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Iagaru</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.</article-title>
            <source>Radiology</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>288</volume>
            <issue>2</issue>
            <fpage>495</fpage>
            <page-range>495-505</page-range>
            <pub-id pub-id-type="pmid">29786490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pianou</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Stavrou</surname>
                <given-names>PZ</given-names>
              </name>
              <name>
                <surname>Vlontzou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rondogianni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Exarhos</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Datseris</surname>
                <given-names>IE</given-names>
              </name>
            </person-group>
            <article-title>More advantages in detecting bone and soft tissue metastases from prostate cancer using <sup>18</sup>F-PSMA PET/CT.</article-title>
            <source>Hell J Nucl Med</source>
            <year>2019</year>
            <season>Jan-Apr</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-9</page-range>
            <pub-id pub-id-type="pmid">30843003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vorster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiele</surname>
                <given-names>Cv</given-names>
              </name>
              <name>
                <surname>Sathekge</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Gallium-68 PET: A Powerful Generator-based Alternative to Infection and Inflammation Imaging.</article-title>
            <source>Semin Nucl Med</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>436</fpage>
            <page-range>436-47</page-range>
            <pub-id pub-id-type="pmid">27553469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Current Status of the Production and Supply of Gallium-68.</article-title>
            <source>Cancer Biother Radiopharm</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>163</fpage>
            <page-range>163-166</page-range>
            <pub-id pub-id-type="pmid">32196363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanchez-Crespo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography.</article-title>
            <source>Appl Radiat Isot</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>76</volume>
            <fpage>55</fpage>
            <page-range>55-62</page-range>
            <pub-id pub-id-type="pmid">23063597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velikyan</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Positron emitting [68Ga]Ga-based imaging agents: chemistry and diversity.</article-title>
            <source>Med Chem</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>345</fpage>
            <page-range>345-79</page-range>
            <pub-id pub-id-type="pmid">21711223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cicoria</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pancaldi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zagni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vichi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dassenno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mora</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lodi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Morigi</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Marengo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Production of Ga-68 with a General Electric PETtrace cyclotron by liquid target.</article-title>
            <source>Phys Med</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>55</volume>
            <fpage>116</fpage>
            <page-range>116-126</page-range>
            <pub-id pub-id-type="pmid">30473059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martiniova</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palatis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Etchebehere</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ravizzini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Gallium-68 in Medical Imaging.</article-title>
            <source>Curr Radiopharm</source>
            <year>2016</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-207</page-range>
            <pub-id pub-id-type="pmid">27804868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bombardieri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aktolun</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Bishof-Delaloye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buscombe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chatal</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Maffioli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moncayo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mortelmans</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reske</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>67Ga scintigraphy: procedure guidelines for tumour imaging.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>12</issue>
            <fpage>BP125</fpage>
            <page-range>BP125-31</page-range>
            <pub-id pub-id-type="pmid">14989225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreasi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Partelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muffatti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Manzoni</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Capurso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on gastroenteropancreatic neuroendocrine tumors.</article-title>
            <source>Dig Liver Dis</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-182</page-range>
            <pub-id pub-id-type="pmid">32912771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>You</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kandathil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Blanche</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kazmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Subramaniam</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.</article-title>
            <source>Nucl Med Commun</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>1060</fpage>
            <page-range>1060-1065</page-range>
            <pub-id pub-id-type="pmid">32732600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>El-Refaie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Win</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Rubello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Al-Nahhas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical indications for Gallium-68 positron emission tomography imaging.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>561</fpage>
            <page-range>561-7</page-range>
            <pub-id pub-id-type="pmid">19201567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chauhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El-Khouli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Waits</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Agrawal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tarter</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Evers</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients.</article-title>
            <source>Oncotarget</source>
            <year>2020</year>
            <month>Aug</month>
            <day>11</day>
            <volume>11</volume>
            <issue>32</issue>
            <fpage>3061</fpage>
            <page-range>3061-3068</page-range>
            <pub-id pub-id-type="pmid">32850010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panagiotidis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alshammari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michopoulou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Skoura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Naik</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maragkoudakis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mohmaduvesh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al-Harbi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bomanji</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.</article-title>
            <source>J Nucl Med</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-96</page-range>
            <pub-id pub-id-type="pmid">27516446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kayani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Conry</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Groves</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Win</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dickson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bomanji</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.</article-title>
            <source>J Nucl Med</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>12</issue>
            <fpage>1927</fpage>
            <page-range>1927-32</page-range>
            <pub-id pub-id-type="pmid">19910422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sasikumar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Specificity of <sup>68</sup>Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality.</article-title>
            <source>Indian J Nucl Med</source>
            <year>2017</year>
            <season>Jan-Mar</season>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-12</page-range>
            <pub-id pub-id-type="pmid">28242976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Love</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Palestro</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Nuclear medicine imaging of bone infections.</article-title>
            <source>Clin Radiol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>632</fpage>
            <page-range>632-46</page-range>
            <pub-id pub-id-type="pmid">26897336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reubi</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Waser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schaer</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Laissue</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.</article-title>
            <source>Eur J Nucl Med</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>836</fpage>
            <page-range>836-46</page-range>
            <pub-id pub-id-type="pmid">11504080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Lely</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Krenning</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Octreoscan radioreceptor imaging.</article-title>
            <source>Endocrine</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-11</page-range>
            <pub-id pub-id-type="pmid">12721512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bozkurt</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Virgolini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Balogova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beheshti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rubello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Decristoforo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ambrosini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kjaer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delgado-Bolton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kunikowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oyen</surname>
                <given-names>WJG</given-names>
              </name>
              <name>
                <surname>Chiti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giammarile</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sundin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Guideline for PET/CT imaging of neuroendocrine neoplasms with <sup>68</sup>Ga-DOTA-conjugated somatostatin receptor targeting peptides and <sup>18</sup>F-DOPA.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>9</issue>
            <fpage>1588</fpage>
            <page-range>1588-1601</page-range>
            <pub-id pub-id-type="pmid">28547177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nanni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Errani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boriani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fantini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ambrosini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Boschi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rubello</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pettinato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>68Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results.</article-title>
            <source>J Nucl Med</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>1932</fpage>
            <page-range>1932-6</page-range>
            <pub-id pub-id-type="pmid">21078801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vorster</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Van deWiele</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sathekge</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Gallium-68: a systematic review of its nononcological applications.</article-title>
            <source>Nucl Med Commun</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>834</fpage>
            <page-range>834-54</page-range>
            <pub-id pub-id-type="pmid">23812409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolmachev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Velikyan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sandstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orlova</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>1356</fpage>
            <page-range>1356-67</page-range>
            <pub-id pub-id-type="pmid">20130858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lindner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kratochwil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title><sup>68</sup>Ga-DOTA-GGNle-CycMSH<sub>hex</sub> targets the melanocortin-1 receptor for melanoma imaging.</article-title>
            <source>Sci Transl Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>07</day>
            <volume>10</volume>
            <issue>466</issue>
            <pub-id pub-id-type="pmid">30404861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Froidevaux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calame-Christe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schuhmacher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tanner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saffrich</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Henze</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eberle</surname>
                <given-names>AN</given-names>
              </name>
            </person-group>
            <article-title>A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases.</article-title>
            <source>J Nucl Med</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-23</page-range>
            <pub-id pub-id-type="pmid">14734683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Croci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Atti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rubagotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Capponi</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Zerbini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saladini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Versari</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Synthesis and characterization of (68)Ga-labeled curcumin and curcuminoid complexes as potential radiotracers for imaging of cancer and Alzheimer's disease.</article-title>
            <source>Inorg Chem</source>
            <year>2014</year>
            <month>May</month>
            <day>19</day>
            <volume>53</volume>
            <issue>10</issue>
            <fpage>4922</fpage>
            <page-range>4922-33</page-range>
            <pub-id pub-id-type="pmid">24766626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zha</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ploessl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kung</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>(68)Ga-Bivalent Polypegylated Styrylpyridine Conjugates for Imaging A&#x003b2; Plaques in Cerebral Amyloid Angiopathy.</article-title>
            <source>Bioconjug Chem</source>
            <year>2016</year>
            <month>May</month>
            <day>18</day>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>1314</fpage>
            <page-range>1314-23</page-range>
            <pub-id pub-id-type="pmid">27045547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johanna Haukkala</surname>
              </name>
              <name>
                <surname>Iina Laitinen</surname>
              </name>
              <name>
                <surname>Pauliina Luoto</surname>
              </name>
              <name>
                <surname>Peter Iveson</surname>
              </name>
              <name>
                <surname>Ian Wilson</surname>
              </name>
              <name>
                <surname>Hege Karlsen</surname>
              </name>
              <name>
                <surname>Alan Cuthbertson</surname>
              </name>
              <name>
                <surname>Jukka Laine</surname>
              </name>
              <name>
                <surname>Pia Lepp&#x000e4;nen</surname>
              </name>
              <name>
                <surname>Yl&#x000e4;-Herttula</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Knuuti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Roivainen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice.</article-title>
            <source>Eur J Nucl Med Mol Imaging</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>2058</fpage>
            <page-range>2058-67</page-range>
            <pub-id pub-id-type="pmid">19629477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaz</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Veit-Haibach</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nuclear medicine and molecular imaging advances in the 21st century.</article-title>
            <source>Br J Radiol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>93</volume>
            <issue>1110</issue>
            <fpage>20200095</fpage>
            <pub-id pub-id-type="pmid">32401541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hofman</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Beauregard</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Barber</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Neels</surname>
                <given-names>OC</given-names>
              </name>
              <name>
                <surname>Eu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy.</article-title>
            <source>J Nucl Med</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>52</volume>
            <issue>10</issue>
            <fpage>1513</fpage>
            <page-range>1513-9</page-range>
            <pub-id pub-id-type="pmid">21908388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Roux</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Siva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA.</article-title>
            <source>Semin Nucl Med</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-81</page-range>
            <pub-id pub-id-type="pmid">30545520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Commandeur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Richard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Renzi</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Severe hypersensitivity reaction to injectable Gallium 67 in a worker exposed to silica.</article-title>
            <source>Allergy</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>4 Pt 1</issue>
            <fpage>337</fpage>
            <page-range>337-9</page-range>
            <pub-id pub-id-type="pmid">1332528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine.</article-title>
            <source>J Nucl Med</source>
            <year>1996</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>185</fpage>
            <page-range>185-92</page-range>
            <pub-id pub-id-type="pmid">8543992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keijsers</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Grutters</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Imaging the inflammatory activity of sarcoidosis.</article-title>
            <source>Eur Respir J</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>743</fpage>
            <page-range>743-51</page-range>
            <pub-id pub-id-type="pmid">23018903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Josefsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Ranka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Plyku</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Willegaignon de Amorim de Carvalho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buchpiguel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sapienza</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Bolch</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Sgouros</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparative Dosimetry for <sup>68</sup>Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors.</article-title>
            <source>J Nucl Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1281</fpage>
            <page-range>1281-1288</page-range>
            <pub-id pub-id-type="pmid">29439017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-125649.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clanton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stabin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Measured human dosimetry of 68Ga-DOTATATE.</article-title>
            <source>J Nucl Med</source>
            <year>2013</year>
            <month>Jun</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>855</fpage>
            <page-range>855-60</page-range>
            <pub-id pub-id-type="pmid">23516312</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
